



**Jean-Michel Chapsal, Dr**

## European Partnership for Alternative Approaches to Animal Testing (EPAA)

Avenue Herrmann-Debroux 40,

1160 Brussels, Belgium

Email: [jmchapsal@gmail.com](mailto:jmchapsal@gmail.com)

Tel: +33 07 82485065

Dr. Jean Michel Chapsal has been working for 30 years at Sanofi Pasteur. Dr Chapsal has led a number of units, including Research and Development, Downstream Processing and Analytical Services-Regulatory Affairs Interface. He has also served recently as Director in Global Analytical Services. His areas of expertise include technical method development for vaccine control, application of emerging technologies in vaccinology, 3Rs alternative methods development, and analytical services in biochemistry, microbiology.

Dr Chapsal received a PhD in Biochemistry from Compiègne University, France. He also completed the general course of Virology at the Institut Pasteur in Paris and received an advanced postgraduate diploma in Virology at Université Paris Diderot. In 1986, he completed a postdoctoral fellowship in the laboratory of Dr Lenore Peirera at the University of California, San Francisco.

Dr Chapsal has been a member of the Working Group on Sera and Human Vaccines of the French Agency for the safety of Health Products (ANSM) and of the French Scientific Interest Group on Alternative methods (GIS). He was co-chair of the International Histamine Test Replacement Working Group for Pertussis vaccine in the frame of the consistency Vaccine Project of the European Partnership for Alternative Approaches to Animal Testing (EPAA). He is currently co-project leader for EDQM (BSP148) and EPAA for the Rabies NIH test replacement and co-chair of the international Rabies Test Replacement Working Group

